About Elite’s GLP-1 & GIP Programs
Semaglutide, the same active pharmaceutical ingredient as Wegovy® & Ozempic® is a glucagon like peptide-1 (GLP-1) agonist, also referred to as an incretin mimetic. GLP-1 agonists were initially developed to improve glycemic control in type 2 diabetes as an adjunct to diet and exercise. It works to enhance the growth of beta cells in the pancreas, which are sites of insulin production. Semaglutide will delay gastric emptying by reducing glucagon secretion in a glucose-dependent manner. The delay in gastric empyting can reduce appetite, improve control of eating, and reduce food cravings. Semaglutide offers glycemic control with improvement to HbA1c levels, moderate weight loss and a significant reduction in risk of major adverse cardiac.
Tirzepatide is the same active pharmaceutical ingredient as Zepbound®/Mounjaro®, a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body’s receptors for GIP and GLP-1, which are natural incretin hormones. It enhances the insulin response, suppresses glucagon secretion, promotes satiety and improves insulin sensitivity.